Literature DB >> 18688093

Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods?

Jürgen Götz1, Lars M Ittner, Marcus Fändrich, Nicole Schonrock.   

Abstract

In Alzheimer's disease brain, the microtubule-associated protein tau detaches from the microtubules, pathologically interacts with cellular proteins, and eventually forms insoluble aggregates that also bind and trap a myriad of proteins. As these proteins are depleted from the cellular pool, they are unavailable for physiological functions. Thus elevated tau levels are pathogenic, even in the absence of tau aggregation. Whereas it is reasonable to assume that tau aggregation is toxic during late stages of disease, the question arises whether early in disease it may be protective. This question can be addressed in tau transgenic animal models in which tau aggregation has been correlated with behavioral impairment. We discuss ways of how tau aggregation is monitored in these mice and what the detection limits are of these methods. We conclude that new tools are needed to measure the different stages of tau aggregation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688093     DOI: 10.3233/jad-2008-14410

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  18 in total

Review 1.  Tau splicing and the intricacies of dementia.

Authors:  Athena Andreadis
Journal:  J Cell Physiol       Date:  2012-03       Impact factor: 6.384

2.  Target gene repression mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by amyloid-β.

Authors:  Nicole Schonrock; David T Humphreys; Thomas Preiss; Jürgen Götz
Journal:  J Mol Neurosci       Date:  2011-07-01       Impact factor: 3.444

3.  Proteasome inhibition drives HDAC6-dependent recruitment of tau to aggresomes.

Authors:  Chris R Guthrie; Brian C Kraemer
Journal:  J Mol Neurosci       Date:  2011-02-22       Impact factor: 3.444

4.  Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.

Authors:  Nicole Schonrock; Yazi D Ke; David Humphreys; Matthias Staufenbiel; Lars M Ittner; Thomas Preiss; Jürgen Götz
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 5.  Modes of Aβ toxicity in Alzheimer's disease.

Authors:  Jürgen Götz; Anne Eckert; Miriam Matamales; Lars M Ittner; Xin Liu
Journal:  Cell Mol Life Sci       Date:  2011-06-25       Impact factor: 9.261

6.  Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity.

Authors:  Anne Eckert; Karen Schmitt; Jürgen Götz
Journal:  Alzheimers Res Ther       Date:  2011-05-05       Impact factor: 6.982

7.  Microtubule assembly by tau impairs endocytosis and neurotransmission via dynamin sequestration in Alzheimer's disease synapse model.

Authors:  Tetsuya Hori; Kohgaku Eguchi; Han-Ying Wang; Tomohiro Miyasaka; Laurent Guillaud; Zacharie Taoufiq; Satyajit Mahapatra; Hiroshi Yamada; Kohji Takei; Tomoyuki Takahashi
Journal:  Elife       Date:  2022-04-26       Impact factor: 8.713

8.  An update on the toxicity of Abeta in Alzheimer's disease.

Authors:  Jürgen Götz; Lars M Ittner; Nicole Schonrock; Roberto Cappai
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

9.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

10.  Amyloid deposits: protection against toxic protein species?

Authors:  Sebastian Treusch; Douglas M Cyr; Susan Lindquist
Journal:  Cell Cycle       Date:  2009-06-20       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.